Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer.

Diaz-Chavez J, Hernandez-Pando R, Lambert PF, Gariglio P.

Mol Cancer. 2008 Jan 9;7:3. doi: 10.1186/1476-4598-7-3.

2.
3.

Effects of human papillomavirus type 16 E7 protein on the growth of cervical carcinoma cells and immuno-escape through the TGF-beta1 signaling pathway.

Xu Q, Wang S, Xi L, Wu S, Chen G, Zhao Y, Wu Y, Ma D.

Gynecol Oncol. 2006 Apr;101(1):132-9. Epub 2005 Nov 2.

PMID:
16269171
5.

Smad2 overexpression reduces the proliferation of the junctional epithelium.

Alotaibi MK, Kitase Y, Shuler CF.

J Dent Res. 2014 Sep;93(9):898-903. doi: 10.1177/0022034514543016. Epub 2014 Jul 14.

6.

Beta-catenin accelerates human papilloma virus type-16 mediated cervical carcinogenesis in transgenic mice.

Bulut G, Fallen S, Beauchamp EM, Drebing LE, Sun J, Berry DL, Kallakury B, Crum CP, Toretsky JA, Schlegel R, Üren A.

PLoS One. 2011;6(11):e27243. doi: 10.1371/journal.pone.0027243. Epub 2011 Nov 7.

8.

Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis.

Shin MK, Balsitis S, Brake T, Lambert PF.

Cancer Res. 2009 Jul 15;69(14):5656-63. doi: 10.1158/0008-5472.CAN-08-3711. Epub 2009 Jul 7.

9.

Neoplastic change of squamo-columnar junction in uterine cervix and vaginal epithelium by exogenous estrogen in hpv-18 URR E6/E7 transgenic mice.

Park JS, Rhyu JW, Kim CJ, Kim HS, Lee SY, Kwon YI, Namkoong SE, Sin HS, Um SJ.

Gynecol Oncol. 2003 Jun;89(3):360-8.

PMID:
12798696
10.

Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors.

Guda K, Giardina C, Nambiar P, Cui H, Rosenberg DW.

Mol Carcinog. 2001 Aug;31(4):204-13.

PMID:
11536370
11.
12.

The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities.

Shai A, Brake T, Somoza C, Lambert PF.

Cancer Res. 2007 Feb 15;67(4):1626-35. Erratum in: Cancer Res. 2007 Apr 1;67(7):3492.

14.

Mechanisms of decreased expression of transforming growth factor-beta receptor type I at late stages of HPV16-mediated transformation.

Hypes MK, Pirisi L, Creek KE.

Cancer Lett. 2009 Sep 18;282(2):177-86. doi: 10.1016/j.canlet.2009.03.014. Epub 2009 Apr 2.

15.

Estrogen contributes to non-pRb targeted HPV18 E7-caused cell proliferation and transformation.

Yan X, Shah W, Li X, Wang Y.

Cancer Biol Ther. 2010 Feb;9(3):206-15. Epub 2010 Feb 16.

PMID:
20009582
16.

Changes in levels of mRNAs of transforming growth factor (TGF)-beta1, -beta2, -beta3, TGF-beta type II receptor and sulfated glycoprotein-2 during apoptosis of mouse uterine epithelium.

Wada K, Nomura S, Morii E, Kitamura Y, Nishizawa Y, Miyake A, Terada N.

J Steroid Biochem Mol Biol. 1996 Dec;59(5-6):367-75.

PMID:
9010342
17.

A role for HPV16 E5 in cervical carcinogenesis.

Maufort JP, Shai A, Pitot HC, Lambert PF.

Cancer Res. 2010 Apr 1;70(7):2924-31. doi: 10.1158/0008-5472.CAN-09-3436. Epub 2010 Mar 23.

18.

Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.

Jakowlew SB, Moody TW, You L, Mariano JM.

Mol Carcinog. 1998 May;22(1):46-56.

PMID:
9609100
19.

Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-dependent expression of transforming growth factor-beta2 in cervical keratinocytes.

Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E, Woodworth CD.

Cancer Res. 2000 Aug 1;60(15):4289-98.

20.

TGF-betaRII rescues development of small intestinal epithelial cells in Elf3-deficient mice.

Flentjar N, Chu PY, Ng AY, Johnstone CN, Heath JK, Ernst M, Hertzog PJ, Pritchard MA.

Gastroenterology. 2007 Apr;132(4):1410-9. Epub 2007 Feb 25.

PMID:
17408644

Supplemental Content

Support Center